CEACAM1 and Hepatic steatosis: Whereas the loss of Ceacam1 by <50% promotes fatty acid β-oxidation, its progressive loss by >50% (after about 3–4 weeks) represses hepatic insulin clearance to cause chronic hyperinsulinemia and ensuing hepatic steatosis and hepatic insulin resistance (Figure 3).